What is Esperion Therapeutics's cumulative cost basis?

Esperion Therapeutics (ESPR) reported cumulative cost basis of $124.21M in Q1 2026.

How has Esperion Therapeutics's cumulative cost basis changed year-over-year?

Esperion Therapeutics's cumulative cost basis increased by 40.4% year-over-year, from $88.46M to $124.21M.

What is the long-term trend for Esperion Therapeutics's cumulative cost basis?

Over 5 years (2020 to 2025), Esperion Therapeutics's cumulative cost basis has grown at a -13.6% compound annual growth rate (CAGR), from $281.78M to $135.64M.

Esperion Therapeutics ESPR Cumulative Cost Basis

Cumulative Cost Basis at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

Lexicon PharmaceuticalsLXRX

——

Zevra Therapeutics, Inc.ZVRA

——

Nurix Therapeutics, Inc.NRIX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's cumulative cost basis?: Esperion Therapeutics (ESPR) reported cumulative cost basis of $124.21M in Q1 2026.
How has Esperion Therapeutics's cumulative cost basis changed year-over-year?: Esperion Therapeutics's cumulative cost basis increased by 40.4% year-over-year, from $88.46M to $124.21M.
What is the long-term trend for Esperion Therapeutics's cumulative cost basis?: Over 5 years (2020 to 2025), Esperion Therapeutics's cumulative cost basis has grown at a -13.6% compound annual growth rate (CAGR), from $281.78M to $135.64M.